CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The UniVax project aims to create a synthetic vaccine using self-replicating RNA technology to enhance immune responses against infections. By targeting immune cells directly, it seeks to provide robust and lasting protection compared to traditional vaccines.
Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection.
Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating.
Their limited antigen loads provide limited capacity for inducing robust immune defences, without assurance that both humoral and cell mediated (CMI) responses, as well as durable immunity, will be induced.
Replicating vaccines may provide several rounds of antigen production, increas…
CONFEDERAZIONE SVIZZERA CONFEDERATION SUISSE SWISS CONFEDERATION
EIDGENOESSISCHES DEPARTEMENT DES INNERN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Marseille
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Russia, MOSKVA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
France, ANGERS
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, MARTINSRIED
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
